Two patients returned to the same PD‐1 inhibitor therapy, including one patient with NSCLC who developed grade 2 dermatitis, retreated with the same PD‐1 inhibitor, and developed CIP after 259 days (Table 5. This evidence concerns the gene PDCD1 and skin disorder.